The White House announced that the Trump administration has extended "most favored nation" pricing to all U.S. Medicaid programs, projected to save nearly $65 billion in Medicaid drug costs over the next decade. This move aims to ensure U.S. drug prices are on par with comparable developed nations and has prompted 26 of the world's largest pharmaceutical manufacturers to commit approximately $170 billion in U.S. investment for manufacturing and R&D. The White House stated that prescription drug prices have seen their largest annual drop in over 60 years, with monthly prices declining throughout 2026.